Neuraxis reports strong first quarter 2025 financial results driven by a 39% growth in revenues

Carmel, ind., may 12, 2025 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended march 31, 2025.

NRXS Ratings Summary

NRXS Quant Ranking